Drug Interactions between digoxin and rifampin
This report displays the potential drug interactions for the following 2 drugs:
- digoxin
- rifampin
Interactions between your drugs
rifAMPin digoxin
Applies to: rifampin and digoxin
MONITOR: Coadministration with rifampin may decrease the plasma concentrations of digoxin. The proposed mechanism is induction of the P-glycoprotein-mediated intestinal efflux and renal tubular secretion of digoxin by rifampin. In 18 healthy volunteers, administration of a single 0.25 mg dose of digoxin following pretreatment with rifampin 300 mg twice a day for 7 days resulted in a 38% decrease in digoxin peak plasma concentration (Cmax) and 25% decrease in systemic exposure (AUC) compared to administration of digoxin alone.
MANAGEMENT: Caution is advised if digoxin is used in combination with rifampin. Digoxin levels should be checked more frequently and the dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of rifampin in patients who are stabilized on their digoxin regimen. Patients should be advised to notify their physician if they experience a worsening of their heart symptoms.
References (12)
- Venkatesan K (1992) "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet, 22, p. 47-65
- Borcherding SM, Baciewicz AM, Self TH (1992) "Update on rifampin drug interactions." Arch Intern Med, 152, p. 711-6
- Bussey HI, Merritt GJ, Hill EG (1984) "The influence of rifampin on quinidine and digoxin." Arch Intern Med, 144, p. 1021-3
- Rodin SM, Johnson BF (1988) "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet, 15, p. 227-44
- Lau AH, Lam NP, Piscitelli SC, et al. (1992) "Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives." Clin Pharmacokinet, 23, p. 328-64
- Marcus FI (1985) "Pharmacokinetic interactions between digoxin and other drugs." J Am Coll Cardiol, 5, a82-90
- Novi C, Bissoli F, Simonati V, Volpini T, Baroli A, Vignati G (1980) "Rifampin and digoxin: possible drug interaction in a dialysis patient." JAMA, 244, p. 2521-2
- Gault H, Longerich L, Dawe RT, Fine A (1984) "Digoxin-rifampin interaction." Clin Pharmacol Ther, 35, p. 750-4
- Baciewicz AM, Self TH, Bekemeyer WB (1987) "Update on rifampin drug interactions." Arch Intern Med, 147, p. 565-8
- Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF (2003) "P-glycoprotein-mediated intestinal and biliary digoxin transport in humans." Clin Pharmacol Ther, 73, p. 223-31
- Greiner B, Eichelbaum M, Fritz P, et al. (1999) "The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin." J Clin Invest, 104, p. 147-53
- Gurley BJ, Swain A, Williams DK, Barone G, Battu SK (2008) "Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics." Mol Nutr Food Res, 52, p. 772-9
Drug and food interactions
rifAMPin food
Applies to: rifampin
GENERALLY AVOID: Concurrent use of rifampin in patients who ingest alcohol daily may result in an increased incidence of hepatotoxicity. The increase in hepatotoxicity may be due to an additive risk as both alcohol and rifampin are individually associated with this adverse reaction. However, the exact mechanism has not been established.
ADJUST DOSING INTERVAL: Administration with food may reduce oral rifampin absorption, increasing the risk of therapeutic failure or resistance. In a randomized, four-period crossover phase I study of 14 healthy male and female volunteers, the pharmacokinetics of single dose rifampin 600 mg were evaluated under fasting conditions and with a high-fat meal. Researchers observed that administration of rifampin with a high-fat meal reduced rifampin peak plasma concentration (Cmax) by 36%, nearly doubled the time to reach peak plasma concentration (Tmax) but reduced overall exposure (AUC) by only 6%.
MANAGEMENT: The manufacturer of oral forms of rifampin recommends administration on an empty stomach, 30 minutes before or 2 hours after meals. Patients should be encouraged to avoid alcohol or strictly limit their intake. Patients who use alcohol and rifampin concurrently or have a history of alcohol use disorder may require additional monitoring of their liver function during treatment with rifampin.
References (6)
- (2022) "Product Information. Rifampin (rifAMPin)." Akorn Inc
- (2022) "Product Information. Rifampicin (rifampicin)." Mylan Pharmaceuticals Inc
- (2023) "Product Information. Rifadin (rifampicin)." Sanofi
- (2024) "Product Information. Rifadin (rifaMPICin)." Sanofi-Aventis Australia Pty Ltd
- Peloquin CA, Namdar R, Singleton MD, Nix DE (2024) Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids https://pubmed.ncbi.nlm.nih.gov/9925057/
- (2019) "Product Information. Rofact (rifampin)." Bausch Health, Canada Inc.
digoxin food
Applies to: digoxin
Administration of digoxin with a high-fiber meal has been shown to decrease its bioavailability by almost 20%. Fiber can sequester up to 45% of the drug when given orally. Patients should be advised to maintain a regular diet without significant fluctuation in fiber intake while digoxin is being titrated.
Grapefruit juice may modestly increase the plasma concentrations of digoxin. The mechanism is increased absorption of digoxin due to mild inhibition of intestinal P-glycoprotein by certain compounds present in grapefruits. In 12 healthy volunteers, administration of grapefruit juice with and 30 minutes before, as well as 3.5, 7.5, and 11.5 hours after a single digoxin dose (0.5 mg) increased the mean area under the plasma concentration-time curve (AUC) of digoxin by just 9% compared to administration with water. Moreover, P-glycoprotein genetic polymorphism does not appear to influence the magnitude of the effects of grapefruit juice on digoxin. Thus, the interaction is unlikely to be of clinical significance.
References (2)
- Darcy PF (1995) "Nutrient-drug interactions." Adverse Drug React Toxicol Rev, 14, p. 233-54
- Becquemont L, Verstuyft C, Kerb R, et al. (2001) "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther, 70, p. 311-6
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.